CyberKnife radiosurgery for stage I lung cancer: results at 36 months.

PURPOSE The aims of this study were to determine if image-guided robotic stereotactic radiosurgery by CyberKnife Radiosurgery System using ablative radiation doses achieves acceptable local control in medically inoperable patients with early non-small-cell lung cancer (NSCLC) and to evaluate disease-free survival, toxicity, and failure. CyberKnife can deliver the prescribed dose by using many different angles converging on the target, with real-time target tracking through a combined orthogonal radiograph imaging and optic motion tracking system (Synchrony). MATERIALS AND METHODS A review of treatment details and outcomes for 59 patients, ranging in age from 51 years to 96 years, with 61 tumors with histologically proven cancers treated by image-guided robotic stereotactic radiosurgery at the CyberKnife Center of Miami between March 2004 and March 2007 is presented. Target localization and respiratory movement compensation were accomplished using a single fiducial marker placed within the tumor, and the X-Sight and Synchrony systems. Total doses ranged from 15 Gy to 67.5 Gy delivered in 1-5 fractions with an equivalent dose range of 24-110 Gy normalized treatment dose in 2 Gy fractions (alpha/beta = 20 Gy). RESULTS Four patients with stage 1A NSCLC and 2 patients with stage 1B NSCLC had persistent or recurrent disease. All patients tolerated the radiosurgery well, fatigue being the main side effect. Of the 59 patients treated, 51 (86%) were still alive at 1-33-month follow-up. Eight patients have died, 2 of diseases other than cancer progression. CONCLUSION The results indicate that the delivery of precisely targeted ablative radiation doses with surgical precision to limited treatment volumes of lung tumors in a hypofractionated fashion is feasible and safe. Image-guided robotic stereotactic radiosurgery of lung tumors with CyberKnife(R) achieves excellent rates of local disease control with limited toxicity to surrounding tissues and, in many cases, might be curative for patients for whom surgery is not an option.

[1]  M. Melamed,et al.  The effect of surgical treatment on survival from early lung cancer. Implications for screening. , 1992, Chest.

[2]  I. Lax,et al.  Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. , 1995, Acta oncologica.

[3]  M. Anscher,et al.  Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience. , 1998, International journal of radiation oncology, biology, physics.

[4]  J C Rosenwald,et al.  Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. , 2000, International journal of radiation oncology, biology, physics.

[5]  Randomized study of single versus fractionated radiotherapy (RT) in the palliation of non-small cell lung cancer; NCIC CTG SC.15 , 2001 .

[6]  Michael Flentje,et al.  Stereotactic Radiotherapy of Targets in the Lung and Liver , 2001, Strahlentherapie und Onkologie.

[7]  J. Wong,et al.  Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. , 2001, International journal of radiation oncology, biology, physics.

[8]  R. Timmerman,et al.  Observation-only management of early stage, medically inoperable lung cancer: poor outcome. , 2002, Chest.

[9]  Stephanie Frost,et al.  Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. , 2003, Chest.

[10]  Angelika Hoess,et al.  Stereotactic single-dose radiotherapy of stage I non-small-cell lung cancer (NSCLC). , 2003, International journal of radiation oncology, biology, physics.

[11]  Quynh-Thu Le,et al.  Stereotactic radiosurgery for lung tumors: preliminary report of a phase I trial. , 2003, The Annals of thoracic surgery.

[12]  I. Lax,et al.  The role of radiotherapy in treatment of stage I non-small cell lung cancer. , 2003, Lung cancer.

[13]  Seung Do Ahn,et al.  Stereotactic body frame based fractionated radiosurgery on consecutive days for primary or metastatic tumors in the lung. , 2003, Lung cancer.

[14]  Michael Flentje,et al.  Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. , 2004, International journal of radiation oncology, biology, physics.

[15]  Joos V Lebesque,et al.  Regional differences in lung radiosensitivity after radiotherapy for non-small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.

[16]  M. Martel,et al.  Results following treatment to doses of 92.4 or 102.9 Gy on a phase I dose escalation study for non-small cell lung cancer. , 2004, Lung cancer.

[17]  T. Araki,et al.  Stereotactic hypofractionated high‐dose irradiation for stage I nonsmall cell lung carcinoma , 2004, Cancer.

[18]  Single fraction stereotactic radiosurgery (SFSR) for lung tumors - A phase I dose escalation trial , 2004 .

[19]  J. Fowler,et al.  Loss of biological effect in prolonged fraction delivery. , 2004, International journal of radiation oncology, biology, physics.

[20]  Lech Papiez,et al.  Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. , 2005, International journal of radiation oncology, biology, physics.

[21]  Branislav Jeremic,et al.  Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer. , 2005, Lung cancer.

[22]  Masahiro Hiraoka,et al.  Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. , 2005, International journal of radiation oncology, biology, physics.

[23]  K. Johansson,et al.  Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer--mature results for medically inoperable patients. , 2006, Lung cancer.

[24]  Lech Papiez,et al.  Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  W. Mühlnickel,et al.  Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases , 2006, Radiation oncology.

[26]  Jan Nyman,et al.  Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries , 2006, Acta oncologica.

[27]  J. Itami,et al.  Clinical outcomes of single‐fraction stereotactic radiation therapy of lung tumors , 2006, Cancer.

[28]  M. Murphy,et al.  Intra-fraction dose delivery timing during stereotactic radiotherapy can influence the radiobiological effect. , 2007, Medical physics.